vs
南玻集团（CSGS）与PHIBRO ANIMAL HEALTH CORP（PAHC）财务数据对比。点击上方公司名可切换其他公司
PHIBRO ANIMAL HEALTH CORP的季度营收约是南玻集团的1.2倍（$373.9M vs $323.1M），PHIBRO ANIMAL HEALTH CORP净利率更高（7.3% vs 2.2%，领先5.2%），PHIBRO ANIMAL HEALTH CORP同比增速更快（20.9% vs 2.0%），南玻集团自由现金流更多（$55.8M vs $8.3M），过去两年PHIBRO ANIMAL HEALTH CORP的营收复合增速更高（19.2% vs 4.6%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
菲宝罗动物保健公司是一家美国动物健康与矿物质营养企业，主营产品涵盖抗菌药、抗球虫药、驱虫药，以及畜禽营养补充剂、疫苗等。公司下设矿物质营养、功能材料、动物健康三大业务板块，收入主要来源于上述板块，业务遍及美国、拉美、加拿大、欧洲、中东、非洲及亚太地区。
CSGS vs PAHC — 直观对比
营收规模更大
PAHC
是对方的1.2倍
$323.1M
营收增速更快
PAHC
高出18.9%
2.0%
净利率更高
PAHC
高出5.2%
2.2%
自由现金流更多
CSGS
多$47.6M
$8.3M
两年增速更快
PAHC
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $373.9M |
| 净利润 | $7.0M | $27.5M |
| 毛利率 | 50.0% | 35.5% |
| 营业利润率 | 9.0% | 13.5% |
| 净利率 | 2.2% | 7.3% |
| 营收同比 | 2.0% | 20.9% |
| 净利润同比 | -79.7% | 762.1% |
| 每股收益（稀释后） | $0.24 | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSPAHC
| Q4 25 | $323.1M | $373.9M | ||
| Q3 25 | $303.6M | $363.9M | ||
| Q2 25 | $297.1M | $378.7M | ||
| Q1 25 | $299.5M | $347.8M | ||
| Q4 24 | $316.7M | $309.3M | ||
| Q3 24 | $295.1M | $260.4M | ||
| Q2 24 | $290.3M | $273.2M | ||
| Q1 24 | $295.1M | $263.2M |
净利润CSGSPAHC
| Q4 25 | $7.0M | $27.5M | ||
| Q3 25 | $20.5M | $26.5M | ||
| Q2 25 | $12.3M | $17.2M | ||
| Q1 25 | $16.1M | $20.9M | ||
| Q4 24 | $34.5M | $3.2M | ||
| Q3 24 | $19.1M | $7.0M | ||
| Q2 24 | $13.8M | $752.0K | ||
| Q1 24 | $19.5M | $8.4M |
毛利率CSGSPAHC
| Q4 25 | 50.0% | 35.5% | ||
| Q3 25 | 48.1% | 32.9% | ||
| Q2 25 | 49.5% | 29.0% | ||
| Q1 25 | 48.4% | 30.1% | ||
| Q4 24 | 51.3% | 32.9% | ||
| Q3 24 | 49.4% | 32.1% | ||
| Q2 24 | 47.3% | 31.9% | ||
| Q1 24 | 46.5% | 30.2% |
营业利润率CSGSPAHC
| Q4 25 | 9.0% | 13.5% | ||
| Q3 25 | 10.0% | 14.1% | ||
| Q2 25 | 10.0% | 8.9% | ||
| Q1 25 | 9.8% | 9.6% | ||
| Q4 24 | 13.4% | 8.3% | ||
| Q3 24 | 10.8% | 6.8% | ||
| Q2 24 | 8.8% | 6.7% | ||
| Q1 24 | 10.8% | 7.6% |
净利率CSGSPAHC
| Q4 25 | 2.2% | 7.3% | ||
| Q3 25 | 6.7% | 7.3% | ||
| Q2 25 | 4.1% | 4.5% | ||
| Q1 25 | 5.4% | 6.0% | ||
| Q4 24 | 10.9% | 1.0% | ||
| Q3 24 | 6.5% | 2.7% | ||
| Q2 24 | 4.8% | 0.3% | ||
| Q1 24 | 6.6% | 3.2% |
每股收益（稀释后）CSGSPAHC
| Q4 25 | $0.24 | $0.67 | ||
| Q3 25 | $0.73 | $0.65 | ||
| Q2 25 | $0.44 | $0.43 | ||
| Q1 25 | $0.57 | $0.51 | ||
| Q4 24 | $1.20 | $0.08 | ||
| Q3 24 | $0.67 | $0.17 | ||
| Q2 24 | $0.48 | $0.02 | ||
| Q1 24 | $0.68 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $74.5M |
| 总债务越低越好 | $539.5M | $624.2M |
| 股东权益账面价值 | $283.7M | $332.4M |
| 总资产 | $1.5B | $1.4B |
| 负债/权益比越低杠杆越低 | 1.90× | 1.88× |
8季度趋势，按日历期对齐
现金及短期投资CSGSPAHC
| Q4 25 | $180.0M | $74.5M | ||
| Q3 25 | $158.4M | $85.3M | ||
| Q2 25 | $145.9M | $77.0M | ||
| Q1 25 | $136.0M | $70.4M | ||
| Q4 24 | $161.8M | $67.1M | ||
| Q3 24 | $118.4M | $89.8M | ||
| Q2 24 | $110.4M | $114.6M | ||
| Q1 24 | $120.8M | $98.7M |
总债务CSGSPAHC
| Q4 25 | $539.5M | $624.2M | ||
| Q3 25 | $538.6M | $628.0M | ||
| Q2 25 | $537.8M | $631.7M | ||
| Q1 25 | $537.6M | $635.4M | ||
| Q4 24 | $538.5M | $639.1M | ||
| Q3 24 | $539.5M | $295.2M | ||
| Q2 24 | $540.5M | $312.1M | ||
| Q1 24 | $541.5M | — |
股东权益CSGSPAHC
| Q4 25 | $283.7M | $332.4M | ||
| Q3 25 | $289.5M | $311.7M | ||
| Q2 25 | $290.7M | $285.7M | ||
| Q1 25 | $283.1M | $266.0M | ||
| Q4 24 | $282.6M | $246.8M | ||
| Q3 24 | $288.4M | $258.5M | ||
| Q2 24 | $273.3M | $256.6M | ||
| Q1 24 | $269.3M | $270.1M |
总资产CSGSPAHC
| Q4 25 | $1.5B | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.4B | $1.4B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.4B | $966.3M | ||
| Q2 24 | $1.4B | $982.2M | ||
| Q1 24 | $1.3B | $979.0M |
负债/权益比CSGSPAHC
| Q4 25 | 1.90× | 1.88× | ||
| Q3 25 | 1.86× | 2.01× | ||
| Q2 25 | 1.85× | 2.21× | ||
| Q1 25 | 1.90× | 2.39× | ||
| Q4 24 | 1.91× | 2.59× | ||
| Q3 24 | 1.87× | 1.14× | ||
| Q2 24 | 1.98× | 1.22× | ||
| Q1 24 | 2.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $8.3M |
| 自由现金流率自由现金流/营收 | 17.3% | 2.2% |
| 资本支出强度资本支出/营收 | 1.1% | 3.0% |
| 现金转化率经营现金流/净利润 | 8.46× | 0.70× |
| 过去12个月自由现金流最近4个季度 | $141.4M | $47.3M |
8季度趋势，按日历期对齐
经营现金流CSGSPAHC
| Q4 25 | $59.2M | $19.4M | ||
| Q3 25 | $47.9M | $9.3M | ||
| Q2 25 | $37.3M | $21.3M | ||
| Q1 25 | $11.5M | $43.2M | ||
| Q4 24 | $82.5M | $3.1M | ||
| Q3 24 | $39.5M | $12.6M | ||
| Q2 24 | $43.1M | $28.4M | ||
| Q1 24 | $-29.4M | $11.4M |
自由现金流CSGSPAHC
| Q4 25 | $55.8M | $8.3M | ||
| Q3 25 | $43.9M | $-4.5M | ||
| Q2 25 | $34.6M | $8.1M | ||
| Q1 25 | $7.1M | $35.4M | ||
| Q4 24 | $76.6M | $-4.7M | ||
| Q3 24 | $32.0M | $3.0M | ||
| Q2 24 | $38.8M | $15.4M | ||
| Q1 24 | $-34.1M | $1.7M |
自由现金流率CSGSPAHC
| Q4 25 | 17.3% | 2.2% | ||
| Q3 25 | 14.5% | -1.2% | ||
| Q2 25 | 11.6% | 2.1% | ||
| Q1 25 | 2.4% | 10.2% | ||
| Q4 24 | 24.2% | -1.5% | ||
| Q3 24 | 10.8% | 1.2% | ||
| Q2 24 | 13.4% | 5.6% | ||
| Q1 24 | -11.6% | 0.6% |
资本支出强度CSGSPAHC
| Q4 25 | 1.1% | 3.0% | ||
| Q3 25 | 1.3% | 3.8% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 1.5% | 2.2% | ||
| Q4 24 | 1.9% | 2.5% | ||
| Q3 24 | 2.5% | 3.7% | ||
| Q2 24 | 1.5% | 4.8% | ||
| Q1 24 | 1.6% | 3.7% |
现金转化率CSGSPAHC
| Q4 25 | 8.46× | 0.70× | ||
| Q3 25 | 2.34× | 0.35× | ||
| Q2 25 | 3.04× | 1.24× | ||
| Q1 25 | 0.71× | 2.07× | ||
| Q4 24 | 2.39× | 0.97× | ||
| Q3 24 | 2.07× | 1.81× | ||
| Q2 24 | 3.12× | 37.80× | ||
| Q1 24 | -1.51× | 1.36× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
PAHC
| Medicated Feed Additives And Others | $202.1M | 54% |
| Mineral Nutrition | $68.9M | 18% |
| Nutritional Specialties | $50.2M | 13% |
| Vaccines | $37.6M | 10% |
| Performance Products | $15.0M | 4% |
